Drug Profile
Research programme: sialylated immunoglobulins - Momenta Pharmaceuticals
Alternative Names: hsIVIg; Hyper-sialylated IVIg; sFc; Sialylation research program - Momenta; sIVIG; Tetra-Fc-sialylated immunoglobulins - Momenta PharmaceuticalsLatest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Virdante Pharmaceuticals
- Developer Momenta Pharmaceuticals
- Class Anti-inflammatories; Immunoglobulins; Recombinant proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Autoimmune disorders
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (IV)
- 28 Nov 2021 No recent reports of development identified for preclinical development in Inflammation in USA (IV)
- 01 Oct 2020 Momenta Pharmaceuticals has been acquired by Johnson & Johnson